| 2026-08-17 | Press release | UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR- NMIBC |
| 2026-08-05 | Press release | UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights |
| 2026-08-05 | Transcript | Q2 FY26 earnings call transcript |
| 2026-07-29 | Press release | UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026 |
| 2026-07-15 | Press release | UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103 |
| 2026-07-08 | Press release | UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer |
| 2026-06-05 | Press release | UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-02 | Press release | UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution |
| 2026-06-01 | Press release | UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference |
| 2026-05-15 | Press release | UroGen Reports 94.5% Six- Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC | UroGen Pharma, Ltd |
| 2026-05-13 | Press release | ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial |
| 2026-05-07 | Press release | UroGen Pharma to Present at Upcoming Investor Conferences |
| 2026-05-06 | Press release | UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights |
| 2026-04-29 | Press release | UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026 |
| 2026-04-08 | Press release | UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer |
| 2026-03-30 | Press release | Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI |
| 2026-03-13 | Press release | UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence |
| 2026-03-06 | Press release | UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-02 | Press release | UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results |
| 2026-03-02 | Press release | UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors |
| 2026-02-27 | Press release | ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC • EORTC Recurrence Score Analysis from the Pivotal ENVISION Trial to be Presented at the 2026 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO-GU 2026) |
| 2026-02-24 | Press release | UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference |
| 2026-02-23 | Press release | UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026 |
| 2026-02-04 | Press release | UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit |
| 2026-01-05 | Press release | Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy |
| Press release | UroGen Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments |
| Press release | UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| Transcript | Earnings call transcript |